PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition.

PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition. Abstract Text:

Oncogenic RAS mutants such as v-Ha-RAS induce cell cycling, in particular the G1 to S transition, by upregulating cyclin D1 and downregulating p27, an inhibitor for cyclin-dependent kinases (CDKs). PI-3 kinase appears to be involved in the regulation of both cyclin D1 and p27. In this report, using two distinct inhibitors specific for PAK1-3 (CEP-1347 and WR-PAK18), we present the first evidence indicating that the PIX/Rac/CDC42-dependent Ser/Thr kinases PAK1-3, acting downstream of PI-3 kinase and upstream of the Raf/MEK/ERKs kinase cascade, is essential for RAS-induced upregulation of cyclin D1, but not downregulation of p27. Since these PAK-inhibitors block selectively the malignant growth of RAS transformants, in which PAK1 is constitutively activated, but not normal cell growth, it is suggested that RAS transformants are addicted to the high levels of PAK1 for their malignant entry to S phase.

PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cell cycle (Georgetown, Tex.)

VOLUME: 3

Page Numbers: 71-4

Journal Abbreviation: Cell Cycle

ISSN: 1538-4101

DAY: 28

MONTH: Jan

YEAR: 2004

PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101137841

PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition. Keywords Mesh Terms:

KEYWORDS: ras Proteins

MESH TERMS: metabolism

Chemical & Substance for Abstract: PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition. Information

Substance Name: ras Proteins

Registry Number: EC 3.6.5.2

Grant and Affiliation Information for PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition.

AFFILIATION: Ludwig Institute for Cancer Research, Parkville/Melbourne, Australia.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cell Cycle

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition Related Publications

• An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
• Analysis of the conformational change of myosin during ATP hydrolysis using fluorescence resonance energy transfer.
• Atypical depression as a premonitory symptom of migraine managed by an oral contraceptive.
• Chirped nonlinear pulse propagation in a dispersion-compensated system.
• Conformational change of the loop L5 in rice kinesin motor domain induced by nucleotide binding.
• Depression associated with chronic pain: incidence, characteristics, and long-term outcome.
• Effect of abdominal surgery on glucose tolerance, plasma levels of insulin and glycogenic amino acids.
• Formation and characterization of kinesin.ADP.fluorometal complexes.
• Incorporation of an azobenzene derivative into the energy transducing site of skeletal muscle myosin results in photo-induced conformational changes.
• Intermolecular cross-linking of a novel rice Kinesin k16 motor domain with a photoreactive ATP derivative.
• Optimal design of dispersion management for a soliton wavelength-division-multiplexed system.
• PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition.
• Photocontrol of Kinesin ATPase activity using an azobenzene derivative.
• Preparation and characterization of a novel rice plant-specific kinesin.
• Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation.
• Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance.
• The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants.
• The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation.